On 14 September 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product… read more.
A new approach to electrically stimulating the brain can improve the gait of people with Parkinson’s disease (PD), according to a study by Shinshu University in Japan. The… read more.
European medicines regulators are studying the potential risk of neurodevelopmental disorders (NDDs) in children conceived by fathers taking valproate, an epilepsy medicine. Preliminary data suggest a possible association… read more.
Multiple studies have demonstrated the memory-enhancing effects of melatonin and its derivatives in animal models. It is also known that the formation of both short- and long-term memories… read more.
Higher testosterone levels during adolescence are associated with increased involvement of the brain’s anterior prefrontal cortex (aPFC) in emotion control, but the opposite effect occurs during adulthood. In… read more.
Neurologic illnesses, including Alzheimer’s, brain cancer, amyotrophic lateral sclerosis (ALS) and stroke, are among the most dreaded illnesses in medicine and leading causes of disability and death worldwide…. read more.
AbbVie announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of atogepant for the… read more.
SK Biopharmaceuticals said that Health Canada granted a Notice of Compliance for Xcopri (ingredient: cenobamate), its epilepsy drug, approving its application for marketing authorization in Canada. Paladin Labs,… read more.
In an international study co-led by UCLA, scientists have shown that a new targeted therapy drug can extend the amount of time people with a subtype of glioma… read more.
Ketamine taken in the form of a nasal spray may prove a safe and effective treatment for refractory chronic migraine, suggests a single centre study, published in the… read more.
The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington’s disease, when compared to a placebo, according to a recent international study led by UTHealth Houston researcher… read more.
Atogepant, an oral drug approved in the US for the prevention of episodic migraine treatment appears to also be effective for the prevention of chronic migraine. The findings of… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
